{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:50:08Z","timestamp":1773096608292,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1016\/s1359-6101(01)00032-6","type":"journal-article","created":{"date-parts":[[2002,10,14]],"date-time":"2002-10-14T15:12:20Z","timestamp":1034608340000},"page":"155-168","source":"Crossref","is-referenced-by-count":551,"title":["Interleukin-12 in anti-tumor immunity and immunotherapy"],"prefix":"10.1016","volume":"13","author":[{"given":"Mario P","family":"Colombo","sequence":"first","affiliation":[]},{"given":"Giorgio","family":"Trinchieri","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1359-6101(01)00032-6_BIB1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","article-title":"Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity","volume":"13","author":"Trinchieri","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1084\/jem.183.1.147","article-title":"The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells","volume":"183","author":"Ma","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB4","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.4049\/jimmunol.146.9.3074","article-title":"Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells","volume":"146","author":"Wolf","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB5","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1084\/jem.176.5.1387","article-title":"Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells","volume":"176","author":"D\u2019Andrea","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/eji.1830250133","article-title":"Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist","volume":"25","author":"Gillessen","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4049\/jimmunol.154.1.116","article-title":"Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity","volume":"154","author":"Ling","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB8","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.4049\/jimmunol.164.9.4752","article-title":"Biosynthesis and posttranslational regulation of human IL-12","volume":"164","author":"Carra","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","article-title":"The interleukin-12\/interleukin-12-receptor system: role in normal and pathologic immune responses","volume":"16","author":"Gately","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1084\/jem.185.5.817","article-title":"Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells","volume":"185","author":"Szabo","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB11","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1073\/pnas.92.16.7307","article-title":"Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes","volume":"92","author":"Bacon","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB12","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB13","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.278.5343.1623","article-title":"Requirement for valpha14 NKT cells in IL-12-mediated rejection of tumors","volume":"278","author":"Cui","year":"1997","journal-title":"Science"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.0.CO;2-C","article-title":"Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12","volume":"29","author":"Kodama","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB15","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.4049\/jimmunol.165.5.2665","article-title":"The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent","volume":"165","author":"Smyth","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB16","first-page":"1225","article-title":"Interleukin 12 gene therapy of MHC-negative murine melanoma metastases","volume":"58","author":"Nanni","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB17","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1002\/1521-4141(2001010)31:10<3101::AID-IMMU3101>3.0.CO;2-8","article-title":"Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases","volume":"31","author":"Chiodoni","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB18","first-page":"467","article-title":"Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells","volume":"56","author":"Vagliani","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/eji.1830250124","article-title":"CD4 T cells inhibit in vivo CD8-mediated immune response against a murine colon carcinoma transduced with IL-12 genes","volume":"25","author":"Martinotti","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ni0901-816","article-title":"Regulatory T cells in the control of immune pathology","volume":"2","author":"Maloy","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1084\/jem.188.1.133","article-title":"Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte\/macrophage colony-stimulating factor","volume":"188","author":"Zilocchi","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB22","first-page":"4853","article-title":"Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk","volume":"52","author":"Colombo","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB23","first-page":"5812","article-title":"IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases","volume":"58","author":"Rodolfo","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB24","first-page":"146","article-title":"Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha","volume":"74","author":"Musiani","year":"1996","journal-title":"Lab. Invest."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0167-5699(97)80012-6","article-title":"Cytokines, tumour-cell death and immunogenicity: a question of choice","volume":"18","author":"Musiani","year":"1997","journal-title":"Immunol. Today"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jnci\/89.14.1049","article-title":"Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12","volume":"89","author":"Cavallo","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB27","first-page":"830s","article-title":"Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2\/neu transgenic BALB\/c mice","volume":"7","author":"Di Carlo","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.180.1.211","article-title":"Interleukin 12 synergizes with B7\/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells","volume":"180","author":"Kubin","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1084\/jem.180.1.223","article-title":"B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation","volume":"180","author":"Murphy","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB30","first-page":"4980","article-title":"B7-1 and interleukin 12 synergistically induce effective antitumor immunity","volume":"55","author":"Coughlin","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB31","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB32","first-page":"2460","article-title":"The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12","volume":"57","author":"Coughlin","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.7904381","article-title":"The adjuvant effect of interleukin-12 in a vaccine against Leishmania major","volume":"263","author":"Afonso","year":"1994","journal-title":"Science"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/smim.1997.0084","article-title":"IL-12 as an adjuvant for cell-mediated immunity","volume":"9","author":"Scott","year":"1997","journal-title":"Semin. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB35","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1073\/pnas.92.6.2219","article-title":"Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma","volume":"92","author":"Noguchi","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/meth.1999.0836","article-title":"Interleukin-12 as an adjuvant for cancer immunotherapy","volume":"19","author":"Rodolfo","year":"1999","journal-title":"Methods"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB37","first-page":"491","article-title":"Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression","volume":"58","author":"Kurzawa","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB38","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1084\/jem.188.9.1603","article-title":"Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect","volume":"188","author":"Koblish","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4049\/jimmunol.161.1.122","article-title":"Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis","volume":"161","author":"Tarrant","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB40","first-page":"16","article-title":"Studies on the role of interleukin-12 in acute murine toxoplasmosis","volume":"84","author":"Hunter","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/jnci\/87.8.581","article-title":"Inhibition of angiogenesis in vivo by interleukin 12 (see comments)","volume":"87","author":"Voest","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1084\/jem.182.1.155","article-title":"Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo","volume":"182","author":"Angiolillo","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1996.tb52664.x","article-title":"A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12","volume":"795","author":"Angiolillo","year":"1996","journal-title":"Ann. New York Acad. Sci."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jlb.64.3.384","article-title":"Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12","volume":"64","author":"Kanegane","year":"1998","journal-title":"J. Leuko. Biol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB45","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.4049\/jimmunol.156.11.4274","article-title":"Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein","volume":"156","author":"Ushio","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB46","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.4049\/jimmunol.159.5.2125","article-title":"A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma","volume":"159","author":"Ahn","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB47","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1172\/JCI1555","article-title":"Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis","volume":"101","author":"Coughlin","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80585-3","article-title":"Tumor cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis","volume":"9","author":"Coughlin","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB49","first-page":"4882","article-title":"Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12","volume":"59","author":"Gee","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB50","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/bjc.1995.426","article-title":"Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: analysis of drug adducts by fluorescent antibodies vs. bound radioactivity","volume":"72","author":"Koch","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB51","first-page":"2974","article-title":"Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations","volume":"61","author":"Gee","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB52","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood.V93.5.1612","article-title":"Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12","volume":"93","author":"Yao","year":"1999","journal-title":"Blood"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1172\/JCI200110128","article-title":"IFN-gamma and Fas\/FasL are required for the antitumor and antiangiogenic effects of IL-12\/pulse IL-2 therapy","volume":"108","author":"Wigginton","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB54","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4","article-title":"The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion\u2013induction of effector T lymphocytes by the chemokines IP-10 and Mig","volume":"28","author":"Piali","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB55","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.4049\/jimmunol.151.5.2511","article-title":"Modulation of perforin and granzyme messenger RNA expression in human natural killer cells","volume":"151","author":"Salcedo","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1172\/JCI9775","article-title":"Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity","volume":"107","author":"Romagnani","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB57","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1096\/fj.99-0963com","article-title":"Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells","volume":"14","author":"Salcedo","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB58","first-page":"1111","article-title":"Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12","volume":"60","author":"Duda","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB59","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.4049\/jimmunol.166.6.3890","article-title":"IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk","volume":"166","author":"Strasly","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1084\/jem.188.3.589","article-title":"Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2\/neu transgenic mice","volume":"188","author":"Boggio","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB61","first-page":"2809","article-title":"A light, nontoxic interleukin 12 protocol inhibits HER-2\/neu mammary carcinogenesis in BALB\/c transgenic mice with established hyperplasia","volume":"61","author":"Cifaldi","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB62","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2047::AID-CNCR10>3.0.CO;2-E","article-title":"Effects of high dose raloxifene in selected patients with advanced breast carcinoma","volume":"88","author":"Gradishar","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB63","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0959-8049(99)00269-5","article-title":"Tamoxifen for the prevention of breast cancer","volume":"36","author":"Fisher","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB64","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.4049\/jimmunol.165.12.7293","article-title":"IL-12 treatment of endogenously arising murine brain tumors","volume":"165","author":"Roy","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB65","doi-asserted-by":"crossref","first-page":"11798","DOI":"10.1073\/pnas.93.21.11798","article-title":"Effect of interleukin 12 on tumor induction by 3-methylcholanthrene","volume":"93","author":"Noguchi","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB66","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.191.4.661","article-title":"Differential tumor surveillance by natural killer (NK) and NKT cells","volume":"191","author":"Smyth","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB67","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1126\/science.278.5343.1626","article-title":"CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides","volume":"278","author":"Kawano","year":"1997","journal-title":"Science"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB68","first-page":"529","article-title":"KRN7000, a novel immunomodulator, and its antitumor activities","volume":"7","author":"Kobayashi","year":"1995","journal-title":"Oncol. Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB69","first-page":"1202","article-title":"Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000","volume":"58","author":"Nakagawa","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB70","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1084\/jem.189.7.1121","article-title":"The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells","volume":"189","author":"Kitamura","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB71","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1074-7613(01)00144-3","article-title":"Toll meets bacterial CpG\u2013DNA","volume":"14","author":"Wagner","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB72","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB73","first-page":"1678","article-title":"Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response","volume":"6","author":"Gollob","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB74","first-page":"9","article-title":"Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer","volume":"5","author":"Robertson","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/gyno.2001.6255","article-title":"Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study","volume":"82","author":"Hurteau","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB76","first-page":"1183","article-title":"Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB77","first-page":"3983","article-title":"Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer","volume":"5","author":"Portielje","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB78","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0009-9236(99)90083-8","article-title":"Down-regulation of the pharmacokinetic\u2013pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this adaptive response in mice","volume":"65","author":"Rakhit","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB79","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/107999001750169934","article-title":"Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma","volume":"21","author":"Motzer","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB80","first-page":"3559","article-title":"Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12","volume":"60","author":"Mortarini","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB81","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/S1359-6101(01)00032-6_BIB82","first-page":"S109","article-title":"The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy","volume":"3","author":"Lotze","year":"1997","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB83","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1089\/104303401300057388","article-title":"Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study","volume":"12","author":"Kang","year":"2001","journal-title":"Hum. Gene. Ther."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB84","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.4049\/jimmunol.163.3.1690","article-title":"Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine","volume":"163","author":"Rosenberg","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB85","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2001.19.18.3836","article-title":"Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma","volume":"19","author":"Lee","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB86","first-page":"895s","article-title":"Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12","volume":"7","author":"Gajewski","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB87","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.280.5368.1432","article-title":"Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency","volume":"280","author":"Altare","year":"1998","journal-title":"Science"},{"key":"10.1016\/S1359-6101(01)00032-6_BIB88","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1172\/JCI4950","article-title":"Inherited interleukin 12 deficiency in a child with Bacille Calmette-Guerin and Salmonella enteritidis disseminated infection","volume":"102","author":"Altare","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S1359-6101(01)00032-6_BIB89","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4049\/jimmunol.156.3.1095","article-title":"Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo","volume":"156","author":"Fallarino","year":"1996","journal-title":"J. Immunol."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610101000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610101000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T21:07:09Z","timestamp":1680728829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610101000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S1359610101000326"],"URL":"https:\/\/doi.org\/10.1016\/s1359-6101(01)00032-6","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}